Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Blood (2024) 143 (17): 1713–1725.

https://doi.org/10.1182/blood.2023021567

Published: 2024

Includes: Supplemental data

Journal Articles

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Blood (2023) 142 (Supplement 1): 974.

https://doi.org/10.1182/blood-2023-180482

Published: 2023

Journal Articles

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Blood (2023) 142 (Supplement 1): 6037.

https://doi.org/10.1182/blood-2023-180710

Published: 2023

Journal Articles

Retrospective and Observational Study on CAR-T 19 Bridge Therapies in Pediatric, Adolescents and Young Adults <24 Years with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Experience of the Spanish Hematopoietic Stem Cell Trasplantation and Cellular Therapy Group (GETH-TC)

Víctor Galán-Gómez, Berta González-Martínez, Anna Alonso-Saladrigues, Susana Rives, Agueda Molinos Quintana, Jose Antonio Perez Simon, Blanca Herrero-Velasco, Mi Kwon, Pere Barba, Mario Sánchez-Salinas, Lucía López-Corral, Anna Torrent, Rafael Hernani, Odelaisy Leon Triana, Antonio Pérez-Martínez

Blood (2023) 142 (Supplement 1): 6909.

https://doi.org/10.1182/blood-2023-190471

Published: 2023

Journal Articles

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2864.

https://doi.org/10.1182/blood-2023-190128

Published: 2023

Journal Articles

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 3329–3332.

https://doi.org/10.1182/blood-2022-166937

Published: 2022

Journal Articles

Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study

Cristina De Ramón, Jose Angel Hernandez-Rivas, MD PhD, Jose Antonio Rodríguez García, Enrique M. Ocio, MDPhD, María Teresa Gómez-Casares, MD PhD, Javier López Jiménez, MD PhD, Carlos Solano, MD PhD, Joaquín Martínez-López, Anna Sureda, Manuel Jurado, MD PhD, Raul Córdoba, MD PhD, Celina Benavente, Pascual Marco, Jose Antonio Pérez-Simón, MD, Jose Maria Moraleda, MD PhD, Angela Figuera, Emilia Pardal, Cristina Pascual Izquierdo, PhD MD, Ramon Garcia-Sanz

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142292

Published: 2020

Journal Articles

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Nathan H Fowler, MD, Michael Dickinson, DMed Sci, Martin Dreyling, MD, Joaquin Martinez-Lopez, MD, Arne Kolstad, MD PhD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Monalisa Ghosh, MD, Leslie L. Popplewell, MD FACP, Julio C. Chavez, MD, Emmanuel Bachy, MD PhD, Koji Kato, MD PhD, Hideo Harigae, MD PhD, Marie José Kersten, MD PhD, Charalambos Andreadis, MD, Peter A. Riedell, MD, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), Jose Antonio Pérez-Simón, MD, Sarah J. Nagle, MD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, MD, Piers Patten, MD PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz C. Offner, MD PhD, Andreas Viardot, Professor Dr, Pier Luigi Zinzani, MD, Ram Malladi, MBBS(Lond), MRCP(UK), FRCPath, Lida Bubuteishvili Pacaud, MD, Alessandra Forcina, MD, Aiesha Zia, Stephen J. Schuster, MD, Catherine Thieblemont, MD PhD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-138983

Published: 2020

Journal Articles

Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Blood (2020) 136 (Supplement 1): 25–27.

https://doi.org/10.1182/blood-2020-141213

Published: 2020

Journal Articles

Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates

Joaquin Martinez-Lopez, MD PhD, Pau Montesinos, MD PhD, Pilar Martinez Sanchez, Julian Gorrochategui, Jose Luis Rojas, Daniel Primo, PhD, Juan-Miguel Bergua, MD, Rosa M M. Ayala, MD PhD, Maria Calbacho, MD, Nieves López-Muñoz, Evelyn Acuña, MD, Jose Antonio Pérez-Simón, MD, Adolfo de la Fuente, Jaime Perez De Oteyza, MDPhD, Rebeca Rodríguez-Veiga, MD, Blanca Boluda, Isabel Cano, MD, Joan Ballesteros, PhD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-134336

Published: 2020

Journal Articles

Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry

Blood (2019) 134 (Supplement_1): 1321.

https://doi.org/10.1182/blood-2019-128568

Published: 2019

Journal Articles

Prognostic Value of Minimal Residual Disease before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

Olga Pérez-López, MD, Teresa Caballero-Velázquez, MD PhD, Enrique Colado, MD PhD, Sara Alonso, MD, José González-Campos, MD, Concepción Prats-Martín, MD, Nancy Rodríguez-Torres, MD, Virginia Escamilla Gomez, Ildefonso Espigado, MD PhD, Jose Antonio Pérez-Simón

Blood (2018) 132 (Supplement 1): 5733.

https://doi.org/10.1182/blood-2018-99-119437

Published: 2018

Journal Articles

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab

Estefanía García-Guerrero, Tea Gogishvili, Sophia Danhof, Martin Schreder, Celine Pallaud, Jose Antonio Pérez-Simón, Hermann Einsele, Michael Hudecek

Blood (2017) 129 (25): 3386–3388.

https://doi.org/10.1182/blood-2017-03-770776

Published: 2017

Includes: Supplemental data

Journal Articles

Response to Proteosome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study

Blood (2016) 128 (22): 3436.

https://doi.org/10.1182/blood.V128.22.3436.3436

Published: 2016

Journal Articles

Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Tim Somervaille, MD PhD, Olga Salamero, MD, Pau Montesinos, MD PhD, Christophe Willekens, MD, Jose Antonio Perez Simon, MD, Arnaud Pigneux, MD, Christian Recher, MD PhD, Rakesh Popat, Cesar Molinero, MD PhD, Christina Mascaro, PhD, Tamara Maes, PhD, Francesc Bosch, MD PhD

Blood (2016) 128 (22): 4060.

https://doi.org/10.1182/blood.V128.22.4060.4060

Published: 2016

Journal Articles

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis

Blood (2016) 127 (9): 1151–1162.

https://doi.org/10.1182/blood-2015-10-662320

Published: 2016

Includes: Supplemental data

Journal Articles

High Correlation Clinical Responses to 1 st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test

Pau Montesinos, MD, Joan Ballesteros, David Martínez-Cuadrón, Joaquín Martínez-López, Josefina Serrano, Jaime Perez de Oteyza, Pascual Fernández, Gabriela Rodriguez-Macías, Mª Belén Vidriales, Pilar Herrera, MD PhD, Mar Tormo, MD PhD, Juan Bergua, Raimundo García, MD, Susana Vives, Mª Ángeles Fernández, Esperanza Lavilla, MD, Santiago Jimenez, Jose Antonio Pérez-Simón, Adriana Simiele, Ataulfo González, Bernardo J. González, Carmen Burgaleta, Juan Antonio López, Concepción Bethancourt, Guiomar Bautista, Arancha Alonso, Mercedes Colorado, Jordi Sierra, Begoña Navas, José Angel Hernández-Rivas, Juan Antonio Vera, Mª Lourdes Amador, Raúl Cordoba, MD, Adolfo de la Fuente, Fernando Ramos, MD PhD MPH, Carlos Javier Cerveró, Consolación Rayón, Olga Salamero, Edelmira Martí, Aurelio López, Teresa Olavé, Marta Gaspar, Julian Gorrochategui, José Luis Rojas, Cristina Gomez, Pilar Hernández, Alicia Robles, Ignacio Ortega, Jesús Villoria, Federico Moscardó, Iñaki Troconiz, Miguel A. Sanz, MD PhD

Blood (2015) 126 (23): 4837.

https://doi.org/10.1182/blood.V126.23.4837.4837

Published: 2015

Journal Articles

Association Between Uric Acid Levels and Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation

Nuria Martinez-Cibrian, Teresa Garrido, Arturo Pereira, Mauricio Sarmiento, Jose Antonio Pérez-Simón, Rocio Parody, MD, Estefania Perez, Oriana Lopez, Carlos Solano, Jose Luis Piñana, Montserrat Rovira, Francesc Fernandez-Avilés, Maria Suarez-Lledo, Alvaro Urbano-Ispizua, Carmen Martinez, MD PhD

Blood (2015) 126 (23): 5464.

https://doi.org/10.1182/blood.V126.23.5464.5464

Published: 2015

Journal Articles

Molecular Dynamics As a Computational Tool to Study the Immune Reactivity: Identification of Conformational Changes in the Major Histocompatibility Complex

Estefania Garcia Guerrero, Jose Antonio Pérez Simon, Luis Ignacio Sánchez Abarca, Irene Diaz Moreno, Miguel Angel De la rosa, Antonio Diaz Quintana

Blood (2014) 124 (21): 2735.

https://doi.org/10.1182/blood.V124.21.2735.2735

Published: 2014

Journal Articles

Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome

Rocío Parody, MDPhD, Dolores Caballero, Martinez Carmen, MD PhD, Rodrigo Martino, MD PhD, Carlos Solano, Pere Barba, MD, Lucía López-Corral, MD PhD, Oriana Lopez Godino, MD, Lourdes Vazquez, MD, Montserrat Rovira, MD PhD, Francesc Fernandez-Avilés, Albert Esquirol, MD, Irene García Cadenas, José Luís Piñana, David Valcarcel, MD PhD, Francisco J. Marquez-Malaver, Jose Antonio Perez-Simón, MDPhD

Blood (2014) 124 (21): 1165.

https://doi.org/10.1182/blood.V124.21.1165.1165

Published: 2014

NARROW

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Retrospective and Observational Study on CAR-T 19 Bridge Therapies in Pediatric, Adolescents and Young Adults <24 Years with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Experience of the Spanish Hematopoietic Stem Cell Trasplantation and Cellular Therapy Group (GETH-TC)

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)

Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study

Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial

Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates

Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry

Prognostic Value of Minimal Residual Disease before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab

Response to Proteosome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study

Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis

High Correlation Clinical Responses to 1 st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test

Association Between Uric Acid Levels and Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation

Molecular Dynamics As a Computational Tool to Study the Immune Reactivity: Identification of Conformational Changes in the Major Histocompatibility Complex

Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only